Zymeworks (ZYME) Stock Soars as Cancer Drug Shows Promise in Phase 3 Trial

TLDR Zymeworks stock jumped 57% after positive Phase 3 trial results for cancer drug Ziihera in treating HER2-positive gastroesophageal adenocarcinoma Ziihera plus chemotherapy showed statistically improved progression-free survival compared to trastuzumab and chemotherapy in first-line treatment Combined with Tevimbra and chemotherapy, Ziihera demonstrated improved overall survival and progression-free survival versus control group Jazz Pharmaceuticals plans [...]

The post Zymeworks (ZYME) Stock Soars as Cancer Drug Shows Promise in Phase 3 Trial appeared first on Blockonomi.